Case Report

Primary Signet Ring Cell Carcinoma of the Lung with Cerebellar Metastasis Showing Full Response to Cisplatin and Docetaxel Therapy

Onur Kocas,1 Fatih Selcukbiricik,2 Ahmet Bilici,2 Metin Kantetz,2 Serdar Yildiz,1 Suna Avci,1 and Canan Tanik3

1 Division of Internal Medicine, Sisli Education and Research Hospital, 34200 Istanbul, Turkey
2 Division of Medical Oncology, Department of Internal Medicine, Sisli Education and Research Hospital, 34200 Istanbul, Turkey
3 Division of Pathology, Sisli Education and Research Hospital, 34200 Istanbul, Turkey

Correspondence should be addressed to Onur Kocas; onurkocas@gmail.com

Received 14 November 2013; Accepted 11 December 2013; Published 9 January 2014

Academic Editors: F. A. Mauri and M. Romkes

Copyright © 2014 Onur Kocas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Primary signet ring cell carcinoma (SRCC) of the lung is a very rare disease. We describe a new case of primary SRCC of the lung with cerebellar metastasis, which responded well to the therapeutic approach with cisplatin and docetaxel. Case Report. A 41-year-old female patient (nonsmoker) was consulted to our oncology outpatient clinic after cerebellar metastasectomy. The histopathological diagnosis was SRCC metastasis. The primary tumor was unknown. The PET-CT imaging showed a hypermetabolic mass in the right middle lobe of the lung and hypermetabolic mediastinal lymph node stations. Oesophagogastroduodenoscopy and colonoscopy showed no evidence of gastrointestinal system tumor. The clinical diagnosis of primary SRCC of the lung was made and the administration of six rounds of cisplatin and docetaxel treatment was planned. After the chemotherapy the PET-CT scan to evaluate the therapy response showed full metabolic regression of the primary tumor and the mediastinal lymph nodes. There was no evidence of new metastasis. Conclusion. Primary SRCC of the lung is a very rare disease with poor prognosis. There are not many cases in literature and no standardized chemotherapy protocols. Cisplatin and docetaxel may be a good treatment option.

1. Introduction

Primary SRCC of the lung is a very rare disease. First described by Kish et al. in 1989, it is reported that incidence of primary SRCC of the lung varies from 0.14% to 1.9% of all lung cancers [1]. The largest series was taken by Tsuta et al. in which 39 of 2640 surgically resected primary lung carcinomas showed SRCC components. Mean age of the patients was 54.6 years, male to female ratio was 1.16 : 1.00, and 26 patients (66.7%) were smokers. The size of the SRCC component of the tumor positively correlated with the aggressiveness of the tumor and poor outcome. The 5-year survival was 28% [2].

2. Case

A 41-years-old female patient (nonsmoker) was consulted to our oncology outpatient clinic by the neurosurgery clinic after cerebellar metastasectomy. The preop CT scan showed a right cerebellar hypodense lesion with the dimension of 5 × 5 cm (Figure 1).

The histopathological examination of the metastasectomy material showed SRCC metastasis with positive immunostaining for CEA, CK 7, and TTF-1. The immunostaining with CK 20, ER, COX2, CK 14, CDX2, and MUC2 was negative. The histopathological morphology was shown Figures 2(a), 2(b), and 2(c).
In order to find the primary tumor a PET-CT scan, oesophagogastrroduodenoscopy and colonoscopy was planned. The endoscopic evaluation of the gastrointestinal system showed no evidence of tumor. The PET-CT scan showed a 26 × 23 mm sized hypermetabolic lesion (SUVmax: 12.1) in the right middle lobe of the lung, multiple 10 mm sized hypermetabolic lymph nodes (SUVmax: 5.7) at station 10R, and a 21 × 19 mm sized hypermetabolic (SUVmax: 12.4) lymph node at station 11R in the mediastinum. The clinical diagnosis was primary SRCC of the lung. The patient received cranial radiotherapy. After the radiotherapy we decided to administrate the patient six rounds of cisplatin and docetaxel regimen. The PET-CT scan to reevaluate the therapy after the 3 rounds of the chemotherapy showed decreased FDG uptake (SUVmax: 5.1) and a decrease in the size of the primary lesion, which we interpreted as partial regression. The hilar metastatic lymph nodes showed nearly full regression and could barely be visualized in the PET-CT images. We decided to complete the cisplatin and docetaxel protocol. The PET-CT scan after the completion of the chemotherapy showed a decrease in size (19 × 25 mm) and metabolic regression (SUVmax: 2.6) of the primary tumor in the right middle lobe of the lung, there was no hypermetabolic pathological lymphadenopathies in the mediastinum. In the left axilla, a 7 × 14 mm sized nodular lesion with slightly increased FDG uptake (SUVmax: 1.3) was detected. There was no pathological FDG uptake in the rest of the body.

3. Discussion

Primary SRCC of the lung is a very rare disease. The largest series was taken by Tsuta et al. in which 39 of 2640 cases surgically resected primary lung carcinomas showed SRCC components. Mean age of the patients was 54.6 years, male-to-female ratio was 1.16 : 1.00, and twenty six patients (66.7%) were smokers. The size of the SRCC component positively correlated with the aggressiveness of the tumor and poor outcome. The 5-year survival was 28% [2].

Because of the rareness of the disease, it is important to distinguish the primary SRCC of the lung from metastatic SRCC’s from other sites of the body like stomach, colon, breast, urinary tract which are more common.

Immunohistochemical studies and molecular diagnostics should help in making the differential diagnosis. The studies of Merchant et al. with 32 SRCC’s from various organs (17 lung, 5 breast, and 5 stomach and 5 colon) showed that 82.4% of pulmonary SRCC’s were TTF-1 positive and the cytokeratine profile CK 7 +/-CK20 - was identified in 94.1% of the pulmonary SRCC cases. Villin was in 29.4% of the cases positive [3]. Positivity for both TTF-1 and Napsin-A is a strong indicator for pulmonary origin [4, 5].

Hayashi et al. reported 5 cases of primary lung SRCC. 80% of the cases were immunoreactive for lactoferrin, 100%
showed K-Ras mutations, 100% were positive for MUC1 and 100% were negative for MUC2. MUC1, is most commonly seen in SRCC and the solid adenocarcinoma of the lung than in SRCC of other organ sites [6].

Although uncommonly, TTF-1 can also be expressed in carcinomas originating from other primary sites (e.g., colon) [7]. On the other side negativity for TTF-1 does not exclude pulmonary SRCC if the tumor is CK 7, positive. In this case metastatic tumor from other body sites need to be excluded clinically [8]. In our case the tumor was positive for CEA, CK 7 and TTF-1 and negative for CK 20, ER, COX2, CK 14, CDX2, and MUC2. It should also be noted that in 70% of pulmonary adenocarcinomas ALK gene rearrangement can be identified, when the SRCC component is >10% [9]. Shaw et al. demonstrated that ALK thyroxine kinase inhibitor (crizotinib) therapy has positive impact on improved survival [10].

A comprehensive, retrospective population-based analysis of the primary SRCC of the lung with the adenocarcinoma of the lung by Ou et al. showed that the patients with primary SRCC are significantly younger than patients with adenocarcinoma, with a significantly higher proportion of poorly differentiated tumor and stage IV disease and no difference in the distribution of gender and ethnicity. Never smokers comprised a higher proportion of patients with SRCC (30.8%) compared to patients with adenocarcinoma (11.0%). Never smokers with SRCC were younger and had an improved overall survival (median age: 55 years, median overall survival: 8 months) than smokers with SRCC (median age: 59 years, median overall survival: 4.5 months). Patients with SRCC had decreased overall survival compared to adenocarcinoma patients [11]. Our patient is a 41-year-old, female, never smoker. Seven months after diagnosis and six rounds of cisplatin and docetaxel therapy, she is well and alive with a satisfactory response to chemotherapy.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**References**

[1] J. K. Kish, J. Y. Ro, A. G. Ayala, and M. J. McMurtry, “Primary mucinous adenocarcinoma of the lung with signet-ring cells: a histochemical comparison with signet-ring cell carcinomas of other sites,” *Human Pathology*, vol. 20, no. 11, pp. 1097–1102, 1989.

[2] K. Tsuta, G. Ishii, K. Yoh et al., “Primary lung carcinoma with signet-ring cell carcinoma components: clinicopathological analysis of 39 cases,” *American Journal of Surgical Pathology*, vol. 28, no. 7, pp. 868–874, 2004.

[3] S. H. Merchant, M. B. Amin, P. Tamboli et al., “Primary signet-ring cell carcinoma of lung: immunohistochemical study and comparison with non-pulmonary signet-ring cell carcinomas,” *American Journal of Surgical Pathology*, vol. 25, no. 12, pp. 1515–1519, 2001.

[4] J. Ye, J. J. Findeis-Hosey, Q. Yang et al., “Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung,” *Applied Immunohistochemistry and Molecular Morphology*, vol. 19, no. 4, pp. 313–317, 2011.

[5] N. Fatima, C. Cohen, D. Lawson, and M. T. Siddiqui, “TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks,” *Cancer Cytopathology*, vol. 119, no. 2, pp. 127–133, 2011.

[6] H. Hayashi, H. Kitamura, Y. Nakatani, Y. Inayama, T. Ito, and H. Kitamura, “Primary signet-ring cell carcinoma of the lung: histochemical and immunohistochemical characterization,” *Human Pathology*, vol. 30, no. 4, pp. 378–383, 1999.

[7] B. Xu, N. Thong, D. Tan, and T. Khoury, “Expression of thyroid transcription factor-1 in colorectal carcinoma,” *Applied Immunohistochemistry and Molecular Morphology*, vol. 18, no. 3, pp. 244–249, 2010.

[8] W. Dubinski, N. B. Leighl, M.-S. Tsao, and D. M. Hwang, “Ancillary testing in lung cancer diagnosis,” *Pulmonary Medicine*, vol. 2012, Article ID 249082, 8 pages, 2012.

[9] S. J. Rodig, M. Mino-Kenudson, and S. Dacic, “Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population,” *Clinical Cancer Research*, vol. 15, pp. 5216–5223, 2009.

[10] A. T. Shaw, B. Y. Yeap, B. J. Salomon et al., “Effect of Crizotinib on overall survival in patients with advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized, phase 3 study,” *The Lancet Oncology*, vol. 12, pp. 735–742.

[11] S.-H. I. Ou, A. Ziogas, and J. A. Zell, “Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung,” *Journal of Thoracic Oncology*, vol. 5, no. 4, pp. 420–427, 2010.